We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Correvio Pharma drew a complete response letter from the FDA for its atrial fibrillation treatment Brinavess (vernakalant) because of inadequate safety data. Read More
Drug imports to the U.S from Canada “will have little or no impact on U.S. drug prices,” and will cause problems for Canadians, according to Canada’s acting Ambassador to the U.S., Kirsten Hillman. Read More
The FDA’s warning letters for 2019 once again targeted many familiar GMP failures, such as quality units that either lacked or failed to follow written procedures. Read More
2019 was one of the biggest years on record for pharma mergers and acquisitions, including the third largest acquisition of all time — Bristol-Myers Squibb’s $74 billion acquisition of Celgene. Read More